New combo aims to stop liver cancer from coming back
NCT ID NCT04418401
First seen Feb 19, 2026 · Last updated May 17, 2026 · Updated 13 times
Summary
This early-phase study tested whether combining donafinib with an anti-PD-1 antibody can safely prevent liver cancer from returning after surgery in patients at high risk of recurrence. 30 adults with hepatocellular carcinoma who had their tumor removed 4-8 weeks earlier took part. The goal was to see if this treatment could improve the one-year recurrence-free rate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.